Want graded evidence, not just articles? Visit the Evidence Room
Keep your finger on the pulse of breakthroughs
Our team and providers are operating at the forefront of regenerative research, clinical practice, and care.
Search our databaseOther news
BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells
The authors show that bone marrow–derived mesenchymal stem cells (BM-MSC) can reverse stroke-induced thymic atrophy, restore thymic structure, and normalize peripheral T-cell populations in a mouse tMCAO model.
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.
